SNY Stock Falls After Board Suddenly Makes Leadership Change
Shares of Sanofi SNY were down 4.5% on Feb. 12, after the company announced that it has chosen not to renew the mandate of its current chief executive officer (CEO), Paul Hudson. The board has appointed Belén Garijo as the new CEO, effective April 29, 2026. She will be the first woman to lead the French drugmaker.
Paul Hudson’s last day at the helm of Sanofi will be Feb. 17, 2026. Olivier Charmeil, the company’s current executive vice president, General Medicines, will serve as the interim CEO before Garijo takes over.
Garijo joined Merck KGaA in 2011 and took over as CEO in 2021, becoming the first woman to lead a German company. A Spanish national, she previously worked in a hospital before moving into pharma, holding roles at Abbott Laboratories and later at Sanofi, where she served on the executive committee.
Per some market reports, Sanofi’s sudden move to appoint Belén Garijo as its new CEO did not sit well with investors, as she lacks a proven track record to run big companies.
SNY’s Price Performance
In the past six months, shares of Sanofi have declined 4.1% against the industry’s increase of 28.4%.
Image Source: Zacks Investment Research
Why the Sudden CEO Change & What it Means for SNY
Sanofi is one of the largest and most renowned vaccine makers in the world. The company also holds a blockbuster immunology drug, Dupixent, which has been its growth engine over the years. SNY expects Dupixent to achieve around €22 billion in sales in 2030.
However, it can be inferred that under Paul Hudson, the company might have been lagging in its research and development (R&D) efforts and pipeline innovation, which in a way marked an abrupt end to his tenure as the CEO of Sanofi.
Coupled with the competition in the vaccines segment, the company also faced some major pipeline setbacks in recent times, which have clouded long-term growth visibility. The company also lagged in mergers and acquisitions compared to its peers, which could have added marketed drugs to its commercial portfolio and helped diversify. These challenges may have prompted the board to opt for a leadership reset.
Though markets remain skeptical, upon her appointment, Garijo’s priority will be to improve productivity, governance and innovation in R&D for Sanofi. It remains to be seen whether this transition leads to a turnaround or prolongs uncertainty, especially in R&D efforts, which will likely shape the company’s long-term growth prospects.
Sanofi Price
Sanofi price | Sanofi Quote
SNY's Zacks Rank & Stocks to Consider
Sanofi currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Immunocore IMCR, Alkermes ALKS and Castle Biosciences CSTL, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, Immunocore’s 2026 loss per share estimates have narrowed from 97 cents to 90 cents. IMCR shares have lost 3.7% over the past six months.
Immunocore earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average earnings surprise being 53.96%.
Over the past 60 days, estimates for Alkermes’ 2026 earnings per share have increased from $1.54 to $1.91. ALKS shares have risen 16.2% over the past six months.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average earnings surprise being 4.58%.
Over the past 60 days, Castle Biosciences’ 2026 loss per share estimates have narrowed from $1.06 to 96 cents. CSTL shares have rallied 64.7% over the past six months.
Castle Biosciences’ earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 66.11%.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Tokenized funds expand across chains, yet liquidity remains fragmented – Why?
Japan Reportedly Plans to Double Defense Spending to 3.5% of GDP, Ministry of Defense Denies, Yet Japanese Bond Yields Hit 30-Year High
According to reports, Japanese defense officials have expressed their willingness to significantly increase defense spending during meetings with the United States. One proposal is to raise defense spending to 3.5% of GDP within ten years, while another, lower target is 3%. Japanese officials previously stated that this fiscal year's defense and related expenditures are approximately $68.8 billion, equivalent to about 1.9% of Japan's nominal GDP in 2022.
Besent Defends US Intervention to Buy Yen: Only "Symbolic" Funds Invested; Yen Appreciation Benefits US Exports and Treasury Market
U.S. Treasury Secretary Janet Yellen said on Tuesday that when the U.S. Treasury coordinated with Japan to purchase yen, only a "symbolic" amount of funds was used. She defended this rare intervention in the foreign exchange market.
Overnight US Stocks | Three Major Indexes Fall for Second Consecutive Day, 10-Year Treasury Yield Rises to Highest Level Since 2007, WTI Crude Oil Surges 4%
At the close, the Dow Jones fell 328.09 points, down 0.63%, to 52,093.10 points; the S&P 500 Index fell 34.25 points, down 0.45%, to 7,585.73 points; the Nasdaq fell 204.84 points, down 0.78%, to 25,981.57 points.
Crypto prices
More
